Agios Pharmaceuticals, Inc. (AGIO)
- Previous Close
34.58 - Open
34.90 - Bid 34.47 x 300
- Ask 34.56 x 300
- Day's Range
33.63 - 35.40 - 52 Week Range
19.80 - 35.50 - Volume
785,935 - Avg. Volume
762,693 - Market Cap (intraday)
1.961B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-6.33 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.00
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
www.agios.comRecent News: AGIO
Performance Overview: AGIO
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGIO
Valuation Measures
Market Cap
1.96B
Enterprise Value
1.26B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
71.66
Price/Book (mrq)
2.42
Enterprise Value/Revenue
46.83
Enterprise Value/EBITDA
-3.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
29.4M
Net Income Avi to Common (ttm)
-352.62M
Diluted EPS (ttm)
-6.33
Balance Sheet and Cash Flow
Total Cash (mrq)
776.93M
Total Debt/Equity (mrq)
8.88%
Levered Free Cash Flow (ttm)
--